Skip to main content

Impact of Genetic Variability in Nicotinic Acetylcholine Receptors on Nicotine Addiction and Smoking Cessation Treatment

Buy Article:

$55.00 plus tax (Refund Policy)

Nicotine dependence (ND) is one of the world's leading causes of preventable death. Nicotine addiction and other forms of drug addiction continue to be significant public health problems in the world. Evidence for a genetic influence on smoking behaviour and ND has prompted a search for susceptibility genes. Evidence has recently accumulated that single nucleotide polymorphisms (SNPs) in the genetic region encoding the nicotinic acetylcholine receptor (nAChR) subunits α6, α5, α3, and β4 are associated with smoking and ND. Brain nAChR are a heterogeneous family of ion channels expressed in the various parts of the brain. A number of studies suggest that brain nAChR are critical targets for the development of pharmacotherapy for nicotine and other drug addictions. In this review, we will discuss the nAChR subtypes, their function in response to endogenous brain transmitters, and how their functions are regulated in the presence of nicotine. Additionally, we will provide an overview of the three major pharmacotherapies for smoking cessation (which have demonstrated efficacy) such as: nicotine replacement therapy (NRT), bupropion, and varenicline.

An appreciation of the complexity of nAChR and their regulation will be necessary for the development of nAChR modulators as potential pharmacotherapy for drug addiction. Prevention strategies should be tailored to carriers of SNPs located on chromosome 15q and that are strongly associated with nicotine dependence and risk of lung cancer.



No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Agonist; Alzheimer's disease; Antagonist; Brain Stress Systems; Mental Disorders; Neurochemistry; Nicotine-addiction; Smoking Cessation Treatment; absorption; acetylcholine-secreting neurons; adolescence; aging; agitation; alkaloid cytisine; allosteric receptors; anger; anxiety; anxiolytic; appetite; aromatic amines; aspartic acid; autocrine-proliferative; bupropion; cholinergic axons; cholinergic receptors; decreased heart rate; dose; drug addiction; epithelial cells; extraneuronal cholinergic; extraneuronal cholinergic system; frustration; genetic variants; heterogeneity; homeostasis; inflammatory responses; insomnia; intoxication; ion channels; isomerization; locus coeruleus; lozenges; microRNA; nausea; neuroadaptation; neurobiology; neurons; nicotine; nicotinic receptor; oral inhaler; organic alkaloid; parkinsonian symptoms; placebo; polymorphisms; primary care physicians; psychopharmacological consequences; pulmonary alveolar capillary; pyrrolidine ring; sarcoidosis; sensitization; solubility; stress; transdermal patch; tumour; varenicline; venous circulation

Document Type: Research Article

Publication date: 2011-01-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more